- Home
- USEA vs LYRA Comparison
USEA vs LYRA Comparison
Compare USEA & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- USEA
- LYRA
- Stock Information
- Founded
- USEA 2004
- LYRA 2005
- Country
- USEA Greece
- LYRA United States
- Employees
- USEA N/A
- LYRA N/A
- Industry
- USEA Marine Transportation
- LYRA Medical/Dental Instruments
- Sector
- USEA Consumer Discretionary
- LYRA Health Care
- Exchange
- USEA Nasdaq
- LYRA Nasdaq
- Market Cap
- USEA 16.1M
- LYRA 13.5M
- IPO Year
- USEA N/A
- LYRA 2020
- Fundamental
- Price
- USEA $1.84
- LYRA $0.18
- Analyst Decision
- USEA Strong Buy
- LYRA Buy
- Analyst Count
- USEA 1
- LYRA 5
- Target Price
- USEA $6.00
- LYRA $4.50
- AVG Volume (30 Days)
- USEA 35.6K
- LYRA 1.1M
- Earning Date
- USEA 02-18-2025
- LYRA 03-20-2025
- Dividend Yield
- USEA 16.39%
- LYRA N/A
- EPS Growth
- USEA N/A
- LYRA N/A
- EPS
- USEA N/A
- LYRA N/A
- Revenue
- USEA $46,160,000.00
- LYRA $1,471,000.00
- Revenue This Year
- USEA $27.55
- LYRA N/A
- Revenue Next Year
- USEA $5.76
- LYRA N/A
- P/E Ratio
- USEA N/A
- LYRA N/A
- Revenue Growth
- USEA 11.18
- LYRA 3.37
- 52 Week Low
- USEA $1.63
- LYRA $0.16
- 52 Week High
- USEA $3.00
- LYRA $6.79
- Technical
- Relative Strength Index (RSI)
- USEA 50.46
- LYRA 43.32
- Support Level
- USEA $1.77
- LYRA $0.18
- Resistance Level
- USEA $1.89
- LYRA $0.19
- Average True Range (ATR)
- USEA 0.06
- LYRA 0.01
- MACD
- USEA 0.01
- LYRA -0.00
- Stochastic Oscillator
- USEA 55.56
- LYRA 27.67
About USEA United Maritime Corporation
United Maritime Corp operates as a shipping company currently specializing in the seaborne transportation of dry bulk commodities. It currently operates one LR2 tanker vessel and three Capesize dry bulk vessels, two Kamsarmax dry bulk vessels, and three Panamax dry bulk vessels, with an aggregate cargo-carrying capacity of approximately 1,004,289 dwt.
About LYRA Lyra Therapeutics Inc.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients with ear, nose, and throat diseases. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioresorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver up to six months of continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.